KR102404650B1 - 포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체 - Google Patents

포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체 Download PDF

Info

Publication number
KR102404650B1
KR102404650B1 KR1020167035389A KR20167035389A KR102404650B1 KR 102404650 B1 KR102404650 B1 KR 102404650B1 KR 1020167035389 A KR1020167035389 A KR 1020167035389A KR 20167035389 A KR20167035389 A KR 20167035389A KR 102404650 B1 KR102404650 B1 KR 102404650B1
Authority
KR
South Korea
Prior art keywords
dimethyl
triazolo
pyrazine
benzimidazol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167035389A
Other languages
English (en)
Korean (ko)
Other versions
KR20170005860A (ko
Inventor
라팔 모슈친스키-페트코브스키
루카슈 보자르스키
마치에 비에초렉
야쿱 마에르
실비아 야노브스카
미콜라 마트로카
말고르차타 보르코브스카
필리프 스테파니아크
모니카 람파르스카-프리치비츠
크르치슈토프 두비엘
Original Assignee
셀론 파르마 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀론 파르마 에스.에이. filed Critical 셀론 파르마 에스.에이.
Publication of KR20170005860A publication Critical patent/KR20170005860A/ko
Application granted granted Critical
Publication of KR102404650B1 publication Critical patent/KR102404650B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
KR1020167035389A 2014-05-19 2015-05-14 포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체 Active KR102404650B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.408251 2014-05-19
PL408251A PL408251A1 (pl) 2014-05-19 2014-05-19 Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
PCT/IB2015/053549 WO2015177688A1 (en) 2014-05-19 2015-05-14 Fused triazole derivatives as phosphodiesterase 10a inhibitors

Publications (2)

Publication Number Publication Date
KR20170005860A KR20170005860A (ko) 2017-01-16
KR102404650B1 true KR102404650B1 (ko) 2022-06-02

Family

ID=53434395

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167035389A Active KR102404650B1 (ko) 2014-05-19 2015-05-14 포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체

Country Status (17)

Country Link
US (1) US10138245B2 (enExample)
EP (1) EP3145930B1 (enExample)
JP (1) JP6455947B2 (enExample)
KR (1) KR102404650B1 (enExample)
CN (1) CN106459060B (enExample)
AU (1) AU2015263013B2 (enExample)
CA (1) CA2946258C (enExample)
DK (1) DK3145930T3 (enExample)
EA (1) EA030330B9 (enExample)
ES (1) ES2688084T3 (enExample)
HR (1) HRP20181027T1 (enExample)
HU (1) HUE039847T2 (enExample)
MX (1) MX367647B (enExample)
PL (2) PL408251A1 (enExample)
PT (1) PT3145930T (enExample)
SI (1) SI3145930T1 (enExample)
WO (1) WO2015177688A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017007301A1 (en) * 2015-07-06 2017-01-12 Universiti Sains Malaysia Compound and method for inhibiting sirtuin activities
KR102587382B1 (ko) * 2016-04-29 2023-10-12 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
CN111410657B (zh) * 2019-01-08 2024-05-21 北京鼎材科技有限公司 一种发光材料及其应用
WO2025160629A1 (en) * 2024-01-31 2025-08-07 Certa Therapeutics Pty Ltd Proton sensing gpcr modulators
TW202600564A (zh) * 2024-02-20 2026-01-01 美商依安彼克醫療有限公司 Her2抑制劑之固態形式
CN119707962B (zh) * 2024-12-14 2025-11-11 中山大学 一类氮杂四元环连接的吡唑并吡啶类化合物或其药学上可接受的盐及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011893A2 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8975276B2 (en) * 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol . 55, no. 17, 2012, pages 7299-7331

Also Published As

Publication number Publication date
PL408251A1 (pl) 2015-11-23
EP3145930A1 (en) 2017-03-29
CA2946258A1 (en) 2015-11-26
EP3145930B1 (en) 2018-07-04
PL3145930T3 (pl) 2018-11-30
WO2015177688A1 (en) 2015-11-26
SI3145930T1 (sl) 2018-10-30
PT3145930T (pt) 2018-10-11
HUE039847T2 (hu) 2019-02-28
US20170114064A1 (en) 2017-04-27
DK3145930T3 (en) 2018-09-24
MX367647B (es) 2019-08-29
JP2017521364A (ja) 2017-08-03
MX2016015180A (es) 2017-03-23
AU2015263013A1 (en) 2016-11-17
KR20170005860A (ko) 2017-01-16
CN106459060B (zh) 2019-04-05
HRP20181027T1 (hr) 2018-08-24
AU2015263013B2 (en) 2018-10-04
EA201692264A1 (ru) 2017-04-28
CN106459060A (zh) 2017-02-22
ES2688084T3 (es) 2018-10-30
EA030330B1 (ru) 2018-07-31
US10138245B2 (en) 2018-11-27
JP6455947B2 (ja) 2019-01-23
CA2946258C (en) 2023-06-06
EA030330B9 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
JP6455947B2 (ja) ホスホジエステラーゼ１０ａインヒビターとしての縮合トリアゾール誘導体
DE60117568T2 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
US8975276B2 (en) Inhibitors of PDE10
US9669029B2 (en) Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors
US9266881B2 (en) Triazolopyridinone PDE10 inhibitors
TWI481607B (zh) 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
AU2019294478A1 (en) Heterocyclic and heteroaryl compounds for treating Huntington's disease
US10287293B2 (en) Bicyclic heterocyclic compounds as PDE2 inhibitors
RS54529B1 (sr) Fenoksimetil heterociklična jedinjenja
US20240228489A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US10647727B2 (en) Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
US12139498B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M4
US10195201B2 (en) Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
BR112016027023B1 (pt) Derivados de triazol fundidos como inibidores de fosfodiesterase 10a
HK1177739B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
HK1177745A1 (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
HK1177745B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4